Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women.
Grace MontepiedraSoyeon KimAdriana WeinbergGerhard TheronTimothy R SterlingSylvia M LaCourseSarah BradfordNahida ChakhtouraPatrick Jean-PhilippeScott EvansAmita GuptaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
For TPT, when used by otherwise healthy persons, preventing adverse events is paramount from the perspective of stakeholders. Among pregnant WLWH in high-TB-burden regions, it is important to consider the antepartum antiretroviral regimen taken when deciding when to initiate TPT. Clinical Trials Registration. NCT01494038 (IMPAACT P1078).
Keyphrases
- mycobacterium tuberculosis
- clinical trial
- hiv aids
- hiv infected
- human immunodeficiency virus
- pregnant women
- pulmonary tuberculosis
- birth weight
- hiv positive
- hiv infected patients
- pregnancy outcomes
- case control
- antiretroviral therapy
- phase ii
- risk factors
- open label
- body mass index
- randomized controlled trial
- hepatitis c virus
- gestational age
- weight gain
- electronic health record